Best EMR for Oncology in 2026

Why Oncology Practices Need Specialized EHR

Oncology is not a specialty that can be served by a general-purpose electronic health record. The clinical workflows in a cancer center -- from chemotherapy order management to tumor registry reporting to clinical trial enrollment -- are so fundamentally different from those in primary care or even other medical specialties that forcing a generic EHR into an oncology practice creates dangerous gaps in patient safety, regulatory compliance, and operational efficiency. Selecting the best EHR for oncology requires understanding why these differences exist and what they demand from software.

Chemotherapy is widely recognized as the most complex medication ordering process in all of medicine. Unlike a primary care physician prescribing a single oral medication at a fixed dose, a medical oncologist must build multi-drug regimens where each agent is dosed based on body surface area (BSA), weight, renal function (often using the Calvert formula for carboplatin), or a combination of these factors. Doses change from cycle to cycle based on lab values, toxicity assessments, and treatment response. Cumulative lifetime dose limits apply to drugs like doxorubicin (maximum 450 to 550 mg/m2) and bleomycin (maximum 400 units), and exceeding these thresholds can cause irreversible organ damage. A general-purpose EHR that treats chemotherapy like any other medication order is not just inconvenient -- it is unsafe.

Beyond chemotherapy, oncology practices face documentation requirements that do not exist in other specialties. Clinical trial enrollment demands precise protocol adherence, adverse event reporting to sponsors and the FDA, and documentation that separates standard-of-care treatment from investigational interventions for billing purposes. State cancer registries and the Commission on Cancer require facilities to report staging, treatment, and outcomes data in formats aligned with the American Joint Committee on Cancer (AJCC) staging system. Multidisciplinary tumor board conferences -- where medical oncologists, radiation oncologists, surgical oncologists, pathologists, and radiologists collaborate on treatment decisions -- need structured documentation that captures the reasoning behind each recommendation.

Treatment toxicity monitoring requires ongoing assessment using the Common Terminology Criteria for Adverse Events (CTCAE), with grading scales that range from Grade 1 (mild) to Grade 5 (death). Lab values must be trended across cycles to detect hematologic toxicity -- neutropenia, thrombocytopenia, anemia -- before it reaches dangerous levels. Patient-reported outcomes using instruments like the PRO-CTCAE are increasingly required by both clinical trial protocols and value-based care programs.

Finally, survivorship care planning has become a standard of care. The American Society of Clinical Oncology (ASCO) and the Commission on Cancer require that patients completing active treatment receive a written survivorship care plan documenting their diagnosis, treatment summary, recommended surveillance schedule, potential late effects, and psychosocial resources. An oncology EHR must generate these plans efficiently rather than requiring hours of manual document creation.

---

Critical EHR Features for Oncology

An oncology EHR must deliver capabilities across six functional areas that are either absent or poorly implemented in general-purpose systems. These are not nice-to-have features -- they are operational requirements for any practice treating cancer patients.

Chemotherapy Order Management

The chemotherapy ordering module is the single most important differentiator between an oncology EHR and a general-purpose system. A capable oncology EHR software platform must include:

• NCCN protocol libraries -- pre-built, evidence-based chemotherapy regimen templates aligned with National Comprehensive Cancer Network guidelines, updated at least quarterly as guidelines evolve
• Regimen builders -- tools that allow oncologists to create custom protocols for off-label use, clinical trial regimens, or institutional preferences while maintaining dose-checking safeguards
• Cycle-based scheduling -- the ability to plan multi-week or multi-month treatment courses as a series of cycles rather than individual orders, with automatic scheduling of labs, infusions, and follow-up visits for each cycle
• Dose calculations -- automated BSA calculation (using Mosteller, DuBois, or Haycock formulas as configured), weight-based dosing, renal function-adjusted dosing (Calvert formula for carboplatin, Cockcroft-Gault for renally cleared agents), and dose capping where clinically appropriate
• Cumulative dose tracking -- lifetime dose monitoring for agents with cumulative toxicity limits, with automated alerts when patients approach thresholds (e.g., doxorubicin approaching 450 mg/m2, cisplatin and ototoxicity monitoring)
• Treatment calendars -- visual calendar displays that show the entire planned treatment course, including chemotherapy days, rest days, lab days, imaging, and follow-up visits
• Premedication ordering -- automated inclusion of standard premedications (antiemetics, corticosteroids, hydration protocols) tied to specific regimens, reducing the risk of omission

Clinical Trial Integration

Approximately 8% of adult cancer patients and up to 20% of pediatric cancer patients enroll in clinical trials. For academic medical centers and NCI-designated cancer centers, that figure can exceed 30%. An oncology electronic health records system must support the clinical trial workflow without forcing staff into parallel documentation systems.

Key clinical trial capabilities include:

• Patient eligibility screening -- tools that match patient demographics, diagnosis, staging, biomarker results, and prior treatment history against active trial inclusion and exclusion criteria
• Protocol documentation -- structured templates that separate investigational interventions from standard-of-care treatment in the medical record, a distinction critical for both clinical accuracy and billing compliance
• Adverse event reporting -- CTCAE-graded adverse event capture that maps to FDA MedWatch and sponsor-required reporting formats, with automated alerting for serious adverse events (SAEs) requiring expedited reporting
• Enrollment tracking -- dashboards that track screening, enrollment, active participation, and follow-up status across all active trials, with accrual reporting for institutional review boards and sponsors
• Data capture for trial protocols -- case report form (CRF) data elements integrated into the clinical workflow so that research coordinators can extract required data from the EHR rather than re-entering it into a separate electronic data capture (EDC) system

Tumor Registry and Cancer Reporting

Cancer reporting is not optional. State cancer registries mandate reporting, and facilities seeking accreditation from the Commission on Cancer (CoC) must meet specific data quality and timeliness standards. An oncology EHR must facilitate, not obstruct, this reporting.

• AJCC staging documentation -- structured fields for TNM staging (tumor size, node involvement, metastasis) using the current AJCC 8th edition criteria, with support for both clinical and pathologic staging
• State cancer registry reporting -- automated generation of cancer case abstracts in North American Association of Central Cancer Registries (NAACCR) format for electronic submission to state registries
• Commission on Cancer data requirements -- data elements required for CoC accreditation surveys, including first course of treatment documentation, treatment timelines, and quality measure reporting
• Pathology synoptic reporting integration -- the ability to receive and parse structured pathology reports (College of American Pathologists cancer protocols) and auto-populate staging fields from synoptic pathology data

Treatment Plan Documentation

ASCO and the Commission on Cancer both require that cancer patients receive a written treatment plan before initiating therapy. This plan must document the diagnosis, staging, treatment intent (curative vs. palliative), planned regimens, expected duration, and anticipated side effects.

• ASCO treatment plan templates -- pre-built templates that conform to ASCO's chemotherapy treatment plan and summary format
• Multidisciplinary tumor board documentation -- structured records of tumor board discussions including attendees, case presentations, imaging and pathology reviewed, and consensus recommendations
• Shared decision-making tools -- patient-facing materials that present treatment options, expected outcomes, side effect profiles, and quality-of-life considerations in accessible language
• Treatment consent forms -- chemotherapy-specific informed consent documents that detail the regimen, known risks, alternative treatments, and expected outcomes, integrated into the EHR for electronic signature and storage

Toxicity Monitoring and Supportive Care

Cancer treatment toxicity is expected, but it must be systematically monitored and managed. An oncology EHR must provide tools for real-time toxicity assessment throughout the treatment course.

• CTCAE grading -- structured fields for grading adverse events using the Common Terminology Criteria for Adverse Events (currently version 5.0), with automated dose modification recommendations based on grade thresholds
• Lab trending for hematologic toxicity -- graphical trending of CBC components (absolute neutrophil count, platelets, hemoglobin) across treatment cycles, with alerts for values that trigger dose delays or reductions per protocol guidelines
• Symptom assessment tools -- patient-reported outcome instruments, particularly the PRO-CTCAE, integrated into the clinical workflow via patient portal or tablet check-in
• Antiemetic protocol management -- emetogenic risk classification for each regimen with automated antiemetic protocol recommendations following ASCO or NCCN antiemesis guidelines

Survivorship Care Planning

The transition from active treatment to survivorship is a critical inflection point in cancer care. An oncology EHR must support this transition with structured, thorough documentation.

• ASCO survivorship care plan templates -- treatment summary and survivorship care plan documents that conform to ASCO and CoC standards
• Follow-up surveillance schedules -- evidence-based surveillance protocols (e.g., mammography schedule after breast cancer treatment, CT surveillance after colorectal cancer) with automated appointment scheduling
• Late effects monitoring -- tracking tools for known late effects of specific treatments (cardiotoxicity after anthracyclines, neuropathy after taxanes, secondary malignancies after alkylating agents)
• Transition from active treatment to survivorship -- workflow tools that manage the handoff from oncology to primary care, including communication templates for the patient's PCP

---

Top Oncology EHR Systems Compared (2026)

The oncology EHR market is split between large enterprise platforms with dedicated oncology modules and specialized systems built exclusively for cancer care. Your choice depends on practice size, subspecialty focus, and whether you need to integrate with a broader health system EHR.

Epic Beacon dominates the large cancer center market. If your practice operates within a health system that runs Epic, Beacon is the default choice -- and a strong one. It provides chemotherapy protocol management, treatment plan documentation, and research integration within the broader Epic ecosystem. The limitation is cost: Epic implementations run into the millions, making it impractical for independent community practices.

Flatiron Health OncoEMR is the leading purpose-built oncology EHR for community practices. Originally developed as a cancer-specific platform, Flatiron (now a Roche subsidiary) combines clinical workflow tools with a real-world evidence data platform that supports quality improvement and research participation. If your practice participates in clinical trials or quality programs like the ASCO Quality Oncology Practice Initiative (QOPI), Flatiron's data infrastructure is a significant advantage.

Varian ARIA is the standard for radiation oncology. If your practice includes a radiation therapy department, ARIA's treatment planning integration, fraction tracking, and machine interface capabilities are unmatched. Note that ARIA is a radiation-specific system -- medical oncology practices typically pair ARIA with a separate medical oncology EHR.

iKnowMed, now part of McKesson's Ontada platform, is deeply embedded in the US Oncology Network. Practices that purchase drugs through McKesson distribution and participate in US Oncology's clinical pathways program benefit from tight integration between the EHR, drug purchasing, and pathway compliance tools.

For smaller oncology practices that cannot justify the cost of a purpose-built oncology EHR, general-purpose platforms like athenahealth and NextGen can work with significant customization, but they will never match the chemotherapy ordering safety and cancer reporting capabilities of oncology-specific systems. See our thorough EHR comparison directory for detailed vendor profiles, and use our EHR matching tool to find systems that fit your practice profile.

---

Medical vs. Radiation vs. Surgical Oncology EHR Needs

Oncology is not a single specialty -- it is three distinct disciplines with overlapping but different EHR requirements. Many cancer centers operate across all three subspecialties, which often means running multiple EHR systems or modules that must interoperate.

Medical oncology workflows center on chemotherapy and systemic therapy. The EHR must manage complex drug regimens, infusion center scheduling (chair time, nurse assignments, pharmacy preparation windows), oral oncolytic prescribing and adherence monitoring, and long-term treatment response documentation. Medical oncology practices also handle the highest volume of clinical trial activity, making research integration a priority.

Radiation oncology is technically demanding in ways that are unique across all of medicine. The EHR must interface directly with treatment planning systems (Varian Eclipse, Elekta Monaco, Accuray Precision) and linear accelerators to track prescribed dose, delivered dose per fraction, cumulative dose to target volumes and organs at risk, and treatment verification images. Varian ARIA and Elekta Mosaiq dominate this niche because they integrate directly with their respective hardware platforms.

Surgical oncology has the least specialized EHR landscape. Most surgical oncologists use the same EHR as their hospital's general surgery department, supplemented by cancer-specific templates for operative reports and pathology workflows. The key requirement is tight integration with pathology -- surgical oncology outcomes depend on margin status, lymph node evaluation, and molecular testing results flowing back into the record promptly and in structured format.

---

Oncology Billing Complexity

Oncology billing is among the most complex in healthcare, and an EHR that does not understand the nuances will leave significant revenue on the table while simultaneously creating compliance risk. The financial model of most oncology practices depends on precise billing across multiple revenue streams.

Chemotherapy Administration Codes

Chemotherapy administration billing uses a hierarchy of CPT codes (96401 through 96549) that depend on the route of administration, the number of agents, the infusion duration, and whether the service is an initial or subsequent administration on a given date. A single chemotherapy visit might generate four or five separate administration charges:

• 96413 -- Chemotherapy IV infusion, first hour (first substance/drug)
• 96415 -- Each additional hour of the same drug
• 96417 -- Each additional sequential infusion of a new drug
• 96375/96376 -- Therapeutic IV push for supportive medications

The EHR's billing module must correctly sequence these codes because payers adjudicate them in a specific hierarchy. Billing the most complex service first maximizes reimbursement, while incorrect sequencing triggers denials.

Drug J-Codes and the Buy-and-Bill Model

Most oncology practices operate under a "buy-and-bill" model where the practice purchases chemotherapy drugs at wholesale (or through a Group Purchasing Organization), administers them to patients, and bills the payer for reimbursement using HCPCS J-codes. The margin between acquisition cost and reimbursement is a significant revenue stream for most practices -- and one that requires precise documentation.

Your cancer EHR must track drug inventory, map administered doses to the correct J-code (including NDC-to-J-code crosswalks), and calculate units billed based on the dose administered (many J-codes use non-intuitive unit definitions -- for example, J9035 for bevacizumab is billed per 10 mg, so a 700 mg dose equals 70 billable units).

Same-Day E/M and Chemotherapy Billing

When an oncologist provides an evaluation and management (E/M) service on the same day as chemotherapy administration -- which is common for treatment day assessments -- both services can be billed if the E/M is separately identifiable (modifier 25). The EHR must support documentation that clearly distinguishes the E/M service (clinical decision-making, symptom management, treatment response assessment) from the chemotherapy administration to withstand payer audits.

Radiation Therapy Coding

Radiation oncology billing follows its own code set: treatment planning (77261-77263), simulation (77280-77295), treatment delivery (77385-77387 for IMRT, 77401-77412 for standard delivery), and image guidance (77014, 77387). Weekly on-treatment management visits (77427) are billed per five fractions delivered. The EHR must track fraction counts accurately because billing a management code before five fractions are completed is a compliance violation.

Clinical Trial Billing and Coverage Analysis

Billing for patients on clinical trials requires a coverage analysis (also called a Medicare Coverage Analysis or billing grid) that determines which services are standard of care (billable to the payer), which are investigational (billable to the trial sponsor), and which are provided free by the sponsor. The EHR must flag clinical trial patients and route charges to the correct responsible party based on the coverage analysis. Incorrect routing -- particularly billing Medicare for investigational services -- can trigger False Claims Act liability.

---

Interoperability in Cancer Care

Cancer treatment is inherently multidisciplinary and frequently multi-institutional. A patient may receive surgery at one facility, chemotherapy at a community oncology practice, and radiation therapy at a third location. The oncology EHR must facilitate data sharing across these care settings.

Tumor Board Data Sharing

Multidisciplinary tumor boards require participants to review imaging, pathology, genomic testing results, and prior treatment history before the conference. The EHR should provide a tumor board preparation view that aggregates relevant data into a single presentation format, accessible to all board participants regardless of whether they share the same EHR instance.

Pathology and Radiology Integration

Pathology reports -- particularly synoptic reports following CAP cancer protocols -- contain the staging and biomarker data that drive treatment decisions. The EHR must receive structured pathology data (not just scanned PDF reports) so that staging fields, receptor status (ER/PR/HER2 for breast cancer, PD-L1 for lung cancer, MSI/MMR for colorectal cancer), and molecular panel results populate automatically. Similarly, radiology reports with RECIST 1.1 measurements should flow into the EHR in structured format to support treatment response assessment.

mCODE and Standardized Cancer Data Exchange

The minimal Common Oncology Data Elements (mCODE) standard, developed by the MITRE Corporation in collaboration with ASCO, represents the most significant interoperability advancement for oncology in recent years. mCODE defines a core set of FHIR-based data elements for cancer patients -- including primary cancer condition, TNM staging, tumor markers, genomics, treatments, and outcomes -- that enable standardized data exchange between systems.

An oncology EHR that supports mCODE can participate in emerging data-sharing networks, contribute to CancerLinQ (ASCO's quality reporting and learning platform), and more easily integrate with institutional data warehouses and research platforms. As of 2026, mCODE support is increasingly becoming a differentiator among oncology EHR vendors, and practices should prioritize systems that have implemented or are actively implementing mCODE profiles.

Multi-Facility Care Coordination

For cancer patients receiving care across multiple sites, the EHR must support care coordination workflows that go beyond simple document exchange. This includes shared treatment plans visible to all treating providers, medication reconciliation that accounts for regimens prescribed at external facilities, and referral management that tracks the patient's journey through surgical consultation, radiation planning, and supportive care services.

---

Implementation Considerations

Implementing an oncology EHR is more complex than implementing a general-purpose system because of the volume of clinical content that must be configured before go-live. Practices should plan for a longer implementation timeline -- typically 6 to 12 months for a dedicated oncology EHR, compared to 2 to 4 months for a general-purpose system in a small practice.

Chemotherapy Protocol Library Setup

The protocol library is the foundation of safe chemotherapy ordering. During implementation, your clinical team must review, validate, and approve every protocol template in the system. This includes verifying drug names, doses, dose calculation methods, cycle lengths, pre-medications, supportive care medications, and dose modification rules. For a community oncology practice treating common solid tumors and hematologic malignancies, the initial protocol library typically includes 150 to 300 regimens. This validation process requires dedicated oncologist and pharmacist time and should not be rushed.

Treatment Template Customization

Beyond chemotherapy protocols, the EHR needs templates for new patient consultations, follow-up visits, infusion day assessments, survivorship visits, and palliative care encounters. Each template must capture the data elements required for cancer registry reporting, quality measure documentation, and clinical trial eligibility screening. Building these templates requires input from physicians, advanced practice providers, nurses, and quality staff.

Tumor Registry Interface Configuration

If your practice reports to state cancer registries or maintains CoC accreditation, the interface between the EHR and your tumor registry software (typically METRIQ, C/NET, or Rocky Mountain Cancer Data Systems) must be configured and validated. This includes mapping EHR data fields to NAACCR data items, establishing automated export schedules, and testing data quality with your cancer registrar team.

Clinical Trial Workflow Setup

Practices participating in clinical trials must configure the EHR to support protocol-specific documentation requirements. This includes building order sets for each active trial protocol, creating billing grids that route charges correctly, establishing adverse event reporting workflows, and training research coordinators on EHR-based data capture. The National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) and individual trial sponsors may have specific EHR documentation requirements that must be incorporated.

Staff Training

Oncology EHR training must go deeper than general EHR training because the consequences of errors are more severe. Chemotherapy nurses need training on order verification, infusion pump documentation, and toxicity recording. Pharmacists need training on order review workflows and dose verification. Physicians need training on regimen ordering, treatment plan documentation, and staging. Front desk and billing staff need training on the unique coding requirements described above. Budget for at least 40 hours of role-specific training per staff member, with competency assessments before go-live.

---

Choosing the Right Oncology EHR for Your Practice

The right oncology EHR depends on your practice's size, subspecialty mix, health system affiliation, clinical trial participation, and budget. Here is a simplified decision framework:

• Large academic cancer centers or health system-affiliated practices: Epic Beacon is the market standard, offering full integration with the broader Epic ecosystem and strong research tools. The investment is substantial but justified by the scale and complexity of these organizations.
• Community oncology practices with clinical trial activity: Flatiron Health OncoEMR or iKnowMed provides oncology-specific workflows at a lower price point than Epic, with strong clinical trial and quality reporting capabilities.
• Radiation oncology departments: Varian ARIA or Elekta Mosaiq for radiation-specific workflows, paired with a medical oncology EHR for the systemic therapy side of the practice.
• Small oncology practices with limited budgets: Consider NextGen or athenahealth with oncology-specific customization, but understand that you will sacrifice chemotherapy safety features and cancer reporting automation. Use our EHR matching tool to explore options that fit your budget and requirements.

Regardless of which system you select, prioritize chemotherapy order safety, cancer reporting compliance, and interoperability. These three capabilities will determine whether your EHR supports or hinders your mission of delivering high-quality cancer care.